Project Grant R41AI131784

Islex Therapeutics, LLC received a Phase I Small Business Innovation Research (SBIR) grant of $621,794 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award, dated August 1, 2025, with a completion date of July 31, 2026, supports preclinical development of a first-in-class, islet-targeted therapeutic antibody for Type 1 Diabetes (T1D). The company aims to...

Antiger Therapeutics Inc., a startup biotech company headquartered in Missouri, received a $606,548 SBIR Phase I Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded on August 11, 2025, with completion targeted for January 31, 2027. The company is developing peptide-HLA-DQ8 biologics—innovative protein-based therapeutics comprised of functional multimers designed to selectively...

Federal Project Grant Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Miami School of Medicine's Office of Research Administration a $380,000 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025 through January 31, 2027. The award funds development and preclinical evaluation of PS03, a bifunctional RNA therapeutic designed to prevent Type 1 Diabetes (T1D) by inducing exhaustion in...

Grant Award Summary SNC Therapeutics, Inc. received a $700,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective July 25, 2025 through July 24, 2026. The award funds development and research of rapamycin-loaded polymersomes (RPS), a tolerogenic nanotherapy designed to delay or prevent Type 1 Diabetes (T1D) onset in susceptible populations....

Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Scripps Research Institute a $801,662 Project Grant effective August 15, 2025, through June 30, 2029, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research project investigates the initiation of anti-islet autoimmunity in Type 1 Diabetes (T1D), a CD4 T cell-mediated autoimmune disease, with particular focus on understanding the role...

Federal Project Grant Award Summary Aleutian Therapeutics, Inc. received a $372,067 Project Grant award dated September 7, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports the development of an immune-evasive stem cell line for Type 1 Diabetes (T1DM) regenerative therapy, with research to be conducted in California through August 31, 2026. This...

Federal Project Grant Award Summary The Beckman Research Institute of The City of Hope received a $868,670 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective February 15, 2026, with a completion date of December 31, 2030. The research project focuses on developing novel therapeutic approaches for Type 1 Diabetes (T1D) through the investigation of...

Grant Award Summary The University of Washington received a $3.42 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 25, 2025, with completion expected July 31, 2030. This collaborative research initiative aims to develop artificial intelligence (AI)-designed mini-proteins, termed epibinders, to enhance the efficiency of pancreatic...

Federal Project Grant Award Summary The Beckman Research Institute of the City of Hope received a $153,554 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 15, 2025, with completion targeted for July 31, 2030. The research project, titled "Alpha Cell Heterogeneity: Unveiling Novel Targets for T1D Therapy," will deliver...

Federal Cooperative Agreement Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a Cooperative Agreement of $1,786,925 to the University of Pennsylvania on September 4, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct biomedical research on Type 1 Diabetes (T1D) etiology and pathogenesis. The research project, extending through August 31, 2027, investigates the hypothesis that beta cell death...